Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02603887 · OUTCOME

Clinical Benefit Rate

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma · Source last updated 2026-07-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From cycle 1 to cycle 8, up to 168 days

What was measured

Minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab

Analysis population: Clinical benefit rate is described as minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab. 1 participant of 13 achieved sCR

Groups in this outcome

Treatment (Pembrolizumab)

Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Pembrolizumab)13

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment (Pembrolizumab)1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        1
denoms
  1. counts
    1. group Id
      OG000
      value
      13
    units
    Participants
description
Minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab
groups
  1. description
    Pembrolizumab 200 mg, 30 minute IV infusion every 21 days up to 24 cycles if equal or higher than minor response and without serious adverse events after 8 cycles
    id
    OG000
    title
    Treatment (Pembrolizumab)
param Type
COUNT_OF_PARTICIPANTS
population Description
Clinical benefit rate is described as minor response or better assessed by IMWG criteria for multiple myeloma after 8 cycles of therapy with pembrolizumab. 1 participant of 13 achieved sCR
reporting Status
POSTED
time Frame
From cycle 1 to cycle 8, up to 168 days
title
Clinical Benefit Rate
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice